Literature DB >> 8339401

LDL subclass phenotypes and the insulin resistance syndrome in women.

J V Selby1, M A Austin, B Newman, D Zhang, C P Quesenberry, E J Mayer, R M Krauss.   

Abstract

BACKGROUND: Low-density lipoprotein (LDL) subclass phenotype B, characterized by predominance of small, dense LDL particles, is associated with elevated plasma triglycerides and apolipoprotein B and with lower high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I. Because these abnormalities resemble the dyslipidemia of insulin resistance, we examined associations of LDL subclass phenotype with plasma insulin levels and with other aspects of the insulin resistance syndrome. METHODS AND
RESULTS: LDL subclass phenotypes were determined by gradient gel electrophoresis in 682 female twins aged 30 to 91 years who participated in the second examination of the Kaiser Permanente Women Twins Study. Prevalence of phenotype B and the intermediate phenotype (I) increased strongly with age, obesity, and non-insulin-dependent diabetes. In multivariate analysis of nondiabetic women, phenotype B or I was independently associated with each aspect of the insulin resistance syndrome, including higher plasma triglycerides, waist-hip ratio, fasting and postload insulin levels, and systolic blood pressure and lower HDL cholesterol levels after adjustment for age and body mass index. The prevalence of phenotype B or I rose progressively from 5.6% in women with no manifestations of the insulin resistance syndrome to 100% in women with four syndrome components. In 25 nondiabetic, monozygotic twin pairs discordant for subclass phenotype, the twins with phenotype B (or I) had significantly higher levels of body mass index, waist-hip ratio, and systolic blood pressure than their twins with phenotype A. Thus, nongenetic variation in these risk factors is important in explaining their associations with LDL subclass phenotype.
CONCLUSIONS: Small, dense LDL is an integral feature of the insulin resistance syndrome. Nongenetic (ie, behavioral or environmental) factors are important for the expression of the phenotype and for its association with other heart disease risk factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339401     DOI: 10.1161/01.cir.88.2.381

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance.

Authors:  Brian A Irving; K Sreekumaran Nair; Manivannan Srinivasan
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 3.  Small, dense low-density lipoprotein: risk or myth?

Authors:  Ngoc-Anh Le
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

4.  Thrombophilia in Patients with Hypertriglyceridemia.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  Multilocus genetic determinants of LDL particle size in coronary artery disease families.

Authors:  J I Rotter; X Bu; R M Cantor; C H Warden; J Brown; R J Gray; P J Blanche; R M Krauss; A J Lusis
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

6.  Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins.

Authors:  M A Austin; P J Talmud; L A Luong; L Haddad; I N Day; B Newman; K L Edwards; R M Krauss; S E Humphries
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

7.  Heritability of longitudinal changes in coronary-heart-disease risk factors in women twins.

Authors:  Y Friedlander; M A Austin; B Newman; K Edwards; E I Mayer-Davis; M C King
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

8.  Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.

Authors:  P Knudsen; J Eriksson; S Lahdenperä; J Kahri; L Groop; M R Taskinen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

9.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

10.  A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

Authors:  S M Haffner; L Mykkänen; D Robbins; R Valdez; H Miettinen; B V Howard; M P Stern; R Bowsher
Journal:  Diabetologia       Date:  1995-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.